Vemlidy (Tenofovir Alafenamide) Patent Expiration, LOE Window & CMS Spending

Vemlidy (Tenofovir Alafenamide) by Gilead Sciences: FDA Orange Book core substance LOE 2033-02-15, 1 AB generics, $300.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN208464 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-02-15
Last Listed Patent or Exclusivity Date2033-02-15
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$300.3M
2024 Medicare Part D Spend$199.0M
2024 Medicaid Spend$101.4M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 17.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.